Search results for "Subcutaneous injection"

showing 10 items of 20 documents

Isolation of two triterpenoids and a biflavanone with anti-Inflammatory activity from Schinus molle fruits.

2003

Three compounds with anti-inflammatory activity were isolated from Schinus molle fruits. Two of the compounds were identified as 3- epi-isomasticadienolalic acid ( 1), isomasticadienonalic acid ( 2) and chamaejasmin ( 3). Triterpenes 1 and 2, and biflavanone 3 were tested on two models of mice paw inflammation: one of acute inflammation, induced by subcutaneous injection of either phospholipase A (2) (PLA (2)) or carrageenan in the paws of mice, and one of chronic inflammation in the form of eczema, provoked by repeated administration of TPA to the ears of mice. On the PLA (2)-induced mouse paw oedema, only 2 was active (30 mg/kg, 66 % inhibition at 60 min), whereas all compounds reduced th…

Leukotriene B4medicine.drug_classNeutrophilsAnacardiaceaePharmaceutical SciencePharmacologyCarrageenanAnti-inflammatoryPhospholipases AAnalytical ChemistrySchinus molleSubcutaneous injectionchemistry.chemical_compoundInhibitory Concentration 50MicePhospholipase A2TriterpeneDrug DiscoverymedicineAnimalsEdemaPharmacologychemistry.chemical_classificationFlavonoidsbiologyPlant ExtractsOrganic ChemistryAnti-Inflammatory Agents Non-Steroidalbiology.organism_classificationTriterpenesCarrageenanComplementary and alternative medicinechemistryBiochemistryFruitToxicitybiology.proteinMolecular MedicineTetradecanoylphorbol AcetateFemalePhytotherapyPlanta medica
researchProduct

Lipoic acid lessens Th1-mediated inflammation in lipopolysaccharide-induced uveitis reducing selectively Th1 lymphocytes-related cytokines release

2013

AbstractInflammation results in the production of free radicals. We evaluated the anti-inflammatory and antioxidant capacity of lipoic acid in an experimental uveitis model upon a subcutaneous injection of endotoxin into Lewis rats. The role of oxidative stress in the endotoxin-induced uveitis model is well-known. Besides, the Th1 response classically performs a central part in the immunopathological process of experimental autoimmune uveitis. Exogenous sources of lipoic acid have been shown to exhibit antioxidant and anti-inflammatory properties. Our results show that lipoic acid treatment plays a preventive role in endotoxin-induced oxidative stress at 24 h post-administration and reduced…

LipopolysaccharidesMaleAntioxidantantioxidantLipopolysaccharidemedicine.medical_treatmentInflammationPharmacologymedicine.disease_causeBiochemistryAntioxidantsUveitischemistry.chemical_compoundSubcutaneous injectionmedicineAnimalsInflammationTh1 lymphocytesTh2 lymphocytesThioctic AcidChemistryAnti-Inflammatory Agents Non-SteroidalGeneral MedicineTh1 Cellsmedicine.diseaselipoic acidcytokinesRatsCellular infiltrationLipoic acidDisease Models AnimalRats Inbred LewImmunologyuveitisCytokineslipids (amino acids peptides and proteins)medicine.symptomOxidative stressUveitis
researchProduct

Efficacy of N-acetylcysteine in the prevention of alcohol relapse-like drinking: Study in long-term ethanol-experienced male rats

2021

Alcohol use disorders are chronic and highly relapsing disorders, thus alcoholic patients have a high rate of recidivism for drug use even after long periods of abstinence. The literature points to the potential usefulness of N-acetylcysteine (NAC) in the management of several substance use disorders probably due to its capacity to restore brain homeostasis of the glutamate system disrupted in addiction. However, there is little evidence in the case of alcohol. The aim of this study was to explore the potential anti-relapse efficacy of NAC using the alcohol deprivation effect (ADE) model in long-term experienced rats. Two experiments were performed in male Wistar rats to: (a) test the effic…

Male0301 basic medicineDrugAlcohol DrinkingInjections Subcutaneousmedia_common.quotation_subjectDrug Evaluation PreclinicalAlcoholPharmacologyInfusions Subcutaneous:CIENCIAS DE LA VIDA [UNESCO]ethanol relapse preventionAcetylcysteineRandom Allocation03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundSubcutaneous injection0302 clinical medicinePharmacotherapyalcohol use disordersRecurrenceglutamate neurotransmissionUNESCO::CIENCIAS DE LA VIDAAnimalsMedicineRats Wistarmedia_commonEthanolEthanolbusiness.industryAbstinencealcohol deprivation effecAcetylcysteineRatsSubstance Withdrawal SyndromeAlcoholismRegimen030104 developmental biologychemistryModels Animalbusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

2017

Prevenció; Atac d'angioedema; Inhibidor C1 Prevención; Ataque de angioedema; Inhibidor C1 Prevention; Angioedema attack; C1 inhibitor BACKGROUND: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks. METHODS: We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the …

Male:aminoácidos péptidos y proteínas::péptidos::serpinas::proteínas inactivadoras del complemento C1::proteína inhibidora del complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]0301 basic medicine:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]Enzims proteolítics - InhibidorsSelf AdministrationSeverity of Illness Indexlaw.inventionC1-inhibitorSubcutaneous injection0302 clinical medicineRandomized controlled triallawCross-Over StudiesHereditary Angioedema Types I and IIbiologyEdema - PrevencióGeneral Medicine:Cardiovascular Diseases::Vascular Diseases::Angioedema::Angioedemas Hereditary [DISEASES]AnesthesiaHereditary angioedema:Other subheadings::Other subheadings::/administration & dosage [Other subheadings]Female:Amino Acids Peptides and Proteins::Peptides::Serpins::Complement C1 Inactivator Proteins::Complement C1 Inhibitor Protein [CHEMICALS AND DRUGS]medicine.symptomComplement C1 Inhibitor Protein:enfermedades cardiovasculares::enfermedades vasculares::angioedema::angioedemas hereditarios [ENFERMEDADES]AdultRiskmedicine.medical_specialtyInjections Subcutaneous:Aminoácidos Péptidos y Proteínas::Péptidos::Serpinas::Proteínas Inactivadoras del Complemento 1::Proteína Inhibidora del Complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]Placebo:Other subheadings::Other subheadings::/prevention & control [Other subheadings]03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumans:Therapeutics::Drug Therapy::Drug Administration Routes::Injections::Injections Subcutaneous [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]:Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores]Dose-Response Relationship DrugAngioedemabusiness.industry:Terapéutica::Tratamiento Farmacológico::Vías de Administración de Medicamentos::Inyecciones::Inyecciones Subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Injeccions hipodèrmiquesmedicine.diseaseCrossover studyClinical trial:terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones::inyecciones subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]030104 developmental biology030228 respiratory systembiology.proteinbusinessNew England Journal of Medicine
researchProduct

Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion

2012

Despite the efficacy in reducing acute rejection events in organ transplanted subjects, long term therapy with cyclosporine A is associated with increased atherosclerotic cardiovascular morbidity. We studied whether this drug affects the antiatherogenic process of the reverse cholesterol transport from macrophages in vivo. Cyclosporine A 50 mg/kg/d was administered to C57BL/6 mice by subcutaneous injection for 14 days. Macrophage reverse cholesterol transport was assessed by following [(3)H]-cholesterol mobilization from pre-labeled intraperitoneally injected macrophages, expressing or not apolipoprotein E, to plasma, liver and feces. The pharmacological treatment significantly reduced the …

MaleApolipoprotein EMouselcsh:MedicineCardiovascularBiochemistryFecesMiceSubcutaneous injectionchemistry.chemical_compoundIntestinal Mucosalcsh:ScienceCholesterol 7-alpha-HydroxylaseMultidisciplinaryReverse cholesterol transportAnimal ModelsLipidsIntestinesCholesterolLiverCyclosporineMedicinelipids (amino acids peptides and proteins)Research Articlemedicine.medical_specialtyLipoproteinsTritiumCholesterol 7 alpha-hydroxylaseCardiovascular PharmacologyExcretionApolipoproteins EModel OrganismsIn vivoInternal medicinemedicineAnimalsBiologyCholesterollcsh:RProteinsBiological TransportLipid MetabolismAtherosclerosisSitosterolsSterolMice Inbred C57BLKineticsEndocrinologyGene Expression RegulationchemistryMacrophages Peritoneallcsh:QATP-Binding Cassette TransportersPLoS ONE
researchProduct

Neue Therapieoption für akute hepatische Porphyrien

2021

Was ist neu? Therapie mit Givosiran Givosiran ist ein kleines synthetisches doppelsträngiges siRNA-Fragment mit 20 Basenpaaren Länge. Eine prospektive, randomisierte multizentrische Studie (Envision) zeigte erstmalig die klinische Wirksamkeit von monatlich subkutan applizierten synthetischen RNA-Molekülen („small interfering“ RNA, siRNA) zur Prävention von Attacken bei akuten hepatischen Porphyrien (AHP) 2. Die Koppelung von siRNA-Molekülen an N-Acetyl-Galaktosamin (GalNAc) und die hierdurch leberspezifische Aufnahme durch den Asialoglykoprotein-Rezeptor auf Hepatozyten sind ein Meilenstein in der Hepatologie. Dies führt zu einer hochselektiven Inhibition der Translation der bei AHP überexp…

Small interfering RNAmedicine.medical_specialtybusiness.industryRenal functionGeneral MedicinePharmacologyHepatologymedicine.diseaseSubcutaneous injectionmedicine.anatomical_structurePorphyriaHepatocyteInternal medicinemedicineAsialoglycoprotein receptorClinical efficacybusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

Prolonged-release buprenorphine formulations: Perspectives for clinical practice

2020

International audience; Buprenorphine and methadone are the two main opioid agonist treatments approved for opioid use disorder. Buprenorphine is a partial agonist of the mu opioid receptors, which has been merely available through sublingual form until now. In practice, the use of buprenorphine is smoother than that of methadone, and it induces reduced risks of overdose. However, sublingual buprenorphine also exposes to risks (e.g., withdrawal, misuse) and constraints (e.g., daily intake). Three new galenic formulations of prolonged-release buprenorphine (PRB) are being commercialized and should allow some improvements in patients' comfort and safety. This narrative review aims to describe…

medicine.medical_specialtyDoseNarcotic Antagonists[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthReceptors Opioid mu030226 pharmacology & pharmacyPartial agonistOpioid dependenceDependance aux opioides03 medical and health sciencesSubcutaneous injection0302 clinical medicineProlonged releasemedicineHumansProlonged-releasePharmacology (medical)OpiacésAction prolongeebusiness.industryOpioid use disorderOpioid-Related Disordersmedicine.disease3. Good healthBuprenorphineAnalgesics OpioidOpiatesOpioid[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthEmergency medicinebusinessSubstitutionMethadoneBuprenorphinemedicine.drugMethadone
researchProduct

Interleukin 12 induces activation of fibrinolysis and coagulation in humans

2001

Interleukin 12 (IL-12) has potential efficacy in malignant, infectious and allergic diseases. Its side-effects include activation of coagulation and fibrinolysis, as documented in chimpanzees. We assessed the coagulative and fibrinolytic response in 18 patients with renal cell carcinoma after subcutaneous injection of 0.5 microg/kg recombinant human IL-12. IL-12 induced a fibrinolytic response in 17 patients (94%): plasmin-alpha2-anti-plasmin complexes (PAPc) increased from 11.8 +/- 6.6 nmol/l (mean +/- SD) to a maximum of 18.8 +/- 7.4 nmol/l at 72 h. Baseline levels of tissue plasminogen activator (tPA) and plasminogen-activator inhibitor-I (PAI) were elevated in eight and 14 patients resp…

medicine.medical_specialtyNecrosisbusiness.industrymedicine.medical_treatmentHematologyTissue plasminogen activatorSubcutaneous injectionEndocrinologyCoagulative necrosisCoagulationInternal medicineHemostasisFibrinolysismedicineInterleukin 12medicine.symptombusinessmedicine.drugBritish Journal of Haematology
researchProduct

THU0413 New Formulation with Potential for the Prevention and Treatment of Osteoporosis and Osteoarthritis

2013

Background Osteoarthritis (OA) is a multidimensional disease that affects all anatomical joint structures, particularly cartilage, synovium and subchondral bone. In turn, osteoporosis (OP) is a skeletal disorder characterized by a compromised bone strength which substantially increases the risk of fracture. Both are common disorders which affect quality of life in elderly. Despite this, there is not any drug at the moment for the simultaneous prevention and treatment of osteoporosis and osteoarthritis. Objectives The aim of this study was to investigate the effect of a new formulation in a combined rat model of OP and OA. The formulation (BIS076) contains Vitamin D3, Hydroxyapatite as a sou…

medicine.medical_specialtybusiness.industryButorphanolCartilageImmunologyOsteoporosisUrologyOsteoarthritismedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologySurgerySubcutaneous injectionmedicine.anatomical_structureRheumatologySkeletal disorderSynovitisOvariectomized ratImmunology and AllergyMedicinebusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Inje…

2021

This study evaluated in vitro and in vivo drug release of bedaquiline from in situ forming gels (ISGs) containing 200 mg eq./g bedaquiline fumarate salt prepared with four different grades of poly(d,l-lactide) (PDLLA) or poly(d,l-lactide-co-glycolide) (PLGA) with a lactide/glycolide ratio of 50/50 or 75/25 and acid (A) or ester (E) end-capping in N-methyl-2-pyrrolidone at a polymer/solvent ratio of 20/80% (w/w). Mean in vitro drug release in 0.05 M phosphate buffer pH 7.4 with 1% (w/v) sodium lauryl sulphate was 37.3, 47.1, 53.3, and 62.3% within 28 days for ISGs containing PLGA5050A, PDLLA, PLGA7525A, and PLGA7525E, respectively. The data suggested that drug release was primarily controlle…

porosityBedaquilinein vitro releasePharmaceutical SciencedissolutionPolyethylene glycolArticleDiffusionchemistry.chemical_compoundSubcutaneous injectionPharmacy and materia medicaPharmacokineticsIn vivoPharmacokineticsin situ forming gelsSolubilitybedaquilinesustained releaseinjectableLactidepolymer erosionPharmacology. TherapydiffusionIn vitro releasePolymer erosionRS1-441PLGAInjectablechemistryIn situ forming gelsBedaquilinePorositypharmacokineticsDissolutionNuclear chemistrySustained releasePharmaceutics
researchProduct